Everolimus in poorly differentiated neuroendocrine carcinoma of unknown primary: A case report

Maroun Bou Zerdan; Ramzi Hamouche; Youssef Bouferraa; Camil Chouairy; Dany Gholam

doi:10.1177/2050313X221106987

Everolimus in poorly differentiated neuroendocrine carcinoma of unknown primary: A case report

SAGE Open Med Case Rep. 2022 Jun 24:10:2050313X221106987. doi: 10.1177/2050313X221106987. eCollection 2022.

Authors

Maroun Bou Zerdan¹, Ramzi Hamouche², Youssef Bouferraa³, Camil Chouairy⁴, Dany Gholam⁵

Affiliations

¹ Department of Internal Medicine, SUNY Upstate Medical University, Syracuse, NY, USA.
² Yale-Waterbury Internal Medicine Residency Program, Waterbury, CT, USA.
³ Department of Internal Medicine, Cleveland Clinic Foundation, Cleveland, OH, USA.
⁴ Department of Pathology, Saint George Hospital University Medical Center, Beirut, Lebanon.
⁵ Department of Hematology and Oncology, Saint George Hospital University Medical Center (SGHUMC), Beirut, Lebanon.

Abstract

Malignancies with unknown primaries contribute to a small yet significant percentage of overall tumors. Neuroendocrine carcinomas, a rare disease with a poor prognosis, have been known to present as an unknown primary. Treatment consists of cytotoxic chemotherapy but given the latter's high toxicity profile new treatment options are being explored. In this case report, we describe a case of a patient with poorly differentiated neuroendocrine carcinoma of unknown primary treated with compassionate oral everolimus after his refusal of intravenous chemotherapy.

Keywords: Everolimus; hematology; oncology; poorly differentiated neuroendocrine carcinoma.

Publication types

Case Reports